“[With] some folks, if you don't accurately risk stratify them, you miss your chance to really build that trust as a provider,” says Neil Mistry, MD, MPH.
In this video, Neil Mistry, MD, MPH, and Adam B. Murphy, MD, MBA, MSCI, discuss future research and the take-home message from the abstract, “West-African ancestry can aid prediction of high-grade prostate cancer in Black-tailored risk calculator,” which was presented at the North Central Section of the AUA Annual Meeting in Chicago, Illinois. Mistry is a urology resident and Murphy is an assistant professor of urology and preventive medicine (cancer epidemiology and prevention) at Northwestern University Feinberg School of Medicine in Chicago.
Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Salvage nivolumab/ipilimumab effective in RCC patients unresponsive to upfront nivolumab
February 21st 2023Patients with renal cell carcinoma who had progressive disease or stable disease after frontline nivolumab had a substantial treatment-free survival period following salvage immunotherapy with nivolumab plus ipilimumab.
2 Clarke Drive
Cranbury, NJ 08512